Drug Trial Radar · NCT07142980
A Phase I Study of HRS-7172 in Participants With Advanced Solid Tumors Harboring RAS Mutations or Amplifications
Last checked: Nov 20, 2026Latest source record: Nov 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
120
Planned (sponsor's estimate)
Start
Sep 12, 2025
Primary completion
Dec 2028
Study completion Dec 2028
Sponsor
- Lead sponsor
- Jiangsu HengRui Medicine Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Aug 27, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase I study of HRS-7172 to evaluate safety, tolerability and pharmacokinetics in participants with advanced solid tumors harboring RAS mutations or amplifications.
Conditions
- Advanced Solid Tumors Harboring RAS Mutations or Amplifications
Interventions
HRS-7172 TabletsDrug
HRS-7172 tablets.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence and severity of adverse events (AEs)Time frame: From screening period up to 30 days after the last dose.
- Incidence and severity of serious adverse events (SAEs)Time frame: From screening period up to 30 days after the last dose.
- Dose-limiting toxicity (DLT)Time frame: From day 1 to day 24.
- Maximum tolerated dose (MTD)Time frame: From day 1 to day 24.
- Recommended Phase II Dose (RP2D)Time frame: From day 1 to day 24.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Fudan University Affiliated Cancer Hospital
Shanghai, Shanghai Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.